Cara Therapeutics Inc (NASDAQ: CARA) is -40.09% lower on its value in year-to-date trading and has touched a low of $0.23 and a high of $1.15 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CARA stock was last observed hovering at around $0.46 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.46, the stock is 51.54% and 54.86% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.21 million and changing 1.36% at the moment leaves the stock 1.40% off its SMA200. CARA registered -33.44% loss for a year compared to 6-month gain of 53.48%. The firm has a 50-day simple moving average (SMA 50) of $0.29564 and a 200-day simple moving average (SMA200) of $0.45979.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 45.89% loss in the last 1 month and extending the period to 3 months gives it a 60.34%, and is 78.25% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 39.09% over the week and 15.62% over the month.
Cara Therapeutics Inc (CARA) has around 55 employees, a market worth around $25.77M and $8.69M in sales. Profit margin for the company is -1099.76%. Distance from 52-week low is 105.41% and -59.69% from its 52-week high. The company has generated returns on investments over the last 12 months (-231.35%).
91.0 institutions hold shares in Cara Therapeutics Inc (CARA), with institutional investors hold 33.42% of the company’s shares. The shares outstanding are 54.85M, and float is at 45.77M with Short Float at 0.72%. Institutions hold 28.16% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 2.25 million shares valued at $0.58 million. The investor’s holdings represent 4.1224 of the CARA Shares outstanding. As of 2024-06-30, the second largest holder is DISCIPLINED GROWTH INVESTORS INC /MN with 1.94 million shares valued at $0.5 million to account for 3.546 of the shares outstanding. The other top investors are CHESCAPMANAGER LLC which holds 1.7 million shares representing 3.1181 and valued at over $0.44 million, while FARALLON CAPITAL MANAGEMENT LLC holds 2.8509 of the shares totaling 1.56 million with a market value of $0.4 million.
Cara Therapeutics Inc (CARA) Insider Activity
The most recent transaction is an insider sale by Posner Christopher, the company’s PRESIDENT AND CEO. SEC filings show that Posner Christopher sold 3,668 shares of the company’s common stock on Nov 04 ’24 at a price of $0.29 per share for a total of $1064.0. Following the sale, the insider now owns 0.17 million shares.
Cara Therapeutics Inc disclosed in a document filed with the SEC on Aug 01 ’24 that Posner Christopher (PRESIDENT AND CEO) sold a total of 4,149 shares of the company’s common stock. The trade occurred on Aug 01 ’24 and was made at $0.35 per share for $1452.0. Following the transaction, the insider now directly holds 0.17 million shares of the CARA stock.
Still, SEC filings show that on May 02 ’24, Posner Christopher (PRESIDENT AND CEO) disposed off 3,936 shares at an average price of $0.75 for $2952.0. The insider now directly holds 176,585 shares of Cara Therapeutics Inc (CARA).
